The DOI matches its Crossref record; 53 of the 58 references it cites were found in a registry or an index.
Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP
Abstract
3,4-methylenedioxymethamphetamine (MDMA) is a widely used drug of abuse chemically related to both the amphetamines and mescaline. Laboratory animal studies have shown that MDMA is a potent re-uptake inhibitor and releaser of dopamine and serotonin. Although the subjective and physiological effects of MDMA have been compared to d-amphetamine in humans, no direct comparison with a serotonin releasing agent has been reported and reinforcing effects have not been evaluated. In this paper we report a direct comparison of the reinforcing, subjective, and physiological effects of MDMA (1 and 2 mg/kg) to d-amphetamine (10 and 20 mg), to metachlorophenylpiperazine (mCPP--a serotonin releasing agent (0.5 and 0.75 mg/kg)), and to placebo using a within-subject design in 12 volunteers with moderate MDMA experience. Both the high dose of d-amphetamine and MDMA showed significant reinforcing effects as indicated by high cross-over values on the multiple choice procedure compared to all other treatments. All three drugs showed dose-dependent changes in subjective effects whereas physiological effects were most pronounced for MDMA with almost no changes seen with mCPP. The subjective effects of MDMA were similar both to those of mCPP and d-amphetamine, suggesting that both dopamine and serotonin systems are involved in mediating these effects. In contrast, only the dopaminergic agents, d-amphetamine and MDMA, had reinforcing effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“These studies indicate that MDMA increases feelings related to empathy and sociability, including self-rated friendliness [7–8], extroversion [9–10], closeness to others [11], sociability [7, 12], talkativeness [7–8], amicability, and gregariousness [13], although some of these effects are inconsistent [14–16].”
From Is Ecstasy an “Empathogen”? Effects of +/- 3,4-Methylenedioxymethamphetamine on Prosocial Feelings and Identification of Emotional States in Others (2010) · cites this paper as [7]
Citations
Cites
Martin, W. R., Sloan, J. W., SAPIRA, J. D., & Jasinski, D. R. (1971) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1971122part1245 · Cited by 945
Methods of Assessing the Reinforcing Properties of Abused Drugs
Bozarth, M. A. (1987) · Springer eBooks · doi:10.1007/978-1-4612-4812-5 · Cited by 693
The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs.
Kalant, H. (2001) · Europe PMC (PubMed Central) · Cited by 604
Strassman, R. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950020022002 · Cited by 453
Vollenweider, F. X., Gamma, A., Liechti, M., & Huber, T. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00013-x · Cited by 448
Mas, M., Farré, M., de la Torre, R., Roset, P. N., Segura, J. O., & Camí, J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)34877-3 · Cited by 362
Gender differences in the subjective effects of MDMA
Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001) · Psychopharmacology · doi:10.1007/s002130000648 · Cited by 360
(1988) · PubMed · Cited by 313
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
Gouzoulis‐Mayfrank, E. (2000) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.68.6.719 · Cited by 306
m-Chlorophenylpiperazine as a probe of serotonin function
Kahn, R. S., & Wetzler, S. E. (1991) · Biological Psychiatry · doi:10.1016/0006-3223(91)90184-n · Cited by 293
Curran, H. V., & Travill, R. A. (1997) · Addiction · doi:10.1111/j.1360-0443.1997.tb02951.x · Cited by 284
Liechti, M. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00148-7 · Cited by 248
Increasing MDMA use among college students: results of a national survey
Strote, J., Lee, J. E., & Wechsler, H. (2002) · Journal of Adolescent Health · doi:10.1016/s1054-139x(01)00315-9 · Cited by 245
Camí, J., Farré, M., Mas, M., Roset, P. N., Poudevida, S., Mas, A., San, L., & de la Torre, R. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200008000-00010 · Cited by 234
Cognitive performance and serotonergic function in users of ecstasy
Verkes, R. J., Gijsman, H. J., Pieters, M. S. M., Schoemaker, R. C., de Visser, S. J., Kuijpers, M., Pennings, E. J. M., de Bruin, D., van de Wijngaart, G. F., van Gerven, J., et al. (2001) · Psychopharmacology · doi:10.1007/s002130000563 · Cited by 233
Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans
Harris, D. S., Baggott, M., Mendelson, J. H., Mendelson, J. E., & Jones, R. T. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1131-1 · Cited by 229
Principles of initial experimental drug abuse liability assessment in humans
Griffiths, R. R., Bigelow, G. E., & Ator, N. A. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00098-x · Cited by 192
Drug preference and mood in humans: d-amphetamine
Johanson, C. E., & UHLENHUTH, E. H. (1980) · Psychopharmacology · doi:10.1007/bf00433062 · Cited by 191
Self-citation(±)3,4-Methylenedioxymethamphetamine (‘Ecstasy’)-Induced Serotonin Neurotoxicity: Clinical Studies
McCann, U. D., Eligulashvili, V., & Ricaurte, G. A. (2000) · Neuropsychobiology · doi:10.1159/000026665 · Cited by 190
The subjective effects of MDMA and mCPP in moderate MDMA users
Tancer, M. E., & Johanson, C. (2001) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(01)00146-6 · Cited by 179
Self-citationWhite, S. R. (1996) · Progress in Neurobiology · doi:10.1016/0301-0082(96)00027-5 · Cited by 176
Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00078-2 · Cited by 175
Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans.
Griffiths, R. R., Troisi, J., Silverman, K., & Mumford, G. K. (1993) · PubMed · Cited by 172
Seiden, L. S., & Sabol, K. E. (1996) · PsycEXTRA Dataset · doi:10.1037/e495672006-014 · Cited by 166
Parrott, A. C. (2000) · Neuropsychobiology · doi:10.1159/000026666 · Cited by 151
Gouzoulis‐Mayfrank, E., Thelen, B., Habermeyer, E., Kunert, H. J., Kovar, K. ‐., Lindenblatt, H., Hermle, L., Spitzer, M., & Sass, H. (1999) · Psychopharmacology · doi:10.1007/s002130050860 · Cited by 145
Self-administration of methylenedioxymethamphetamine (MDMA) by rhesus monkeys
Beardsley, P. M., Balster, R. L., & Harris, L. S. (1986) · Drug and Alcohol Dependence · doi:10.1016/0376-8716(86)90047-5 · Cited by 141
Lester, S. J., Baggott, M. J., Welm, S., Schiller, N. B., Jones, R. T., Foster, E., & Mendelson, J. E. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-12-200012190-00012 · Cited by 138
Fantegrossi, W. E., Ullrich, T., Rice, K. C., Woods, J. H., & Winger, G. D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1021-6 · Cited by 132
Griffiths, R., Troisi, J., Silvermian, K., & Miumford, G. K. (1993) · Behavioural Pharmacology · doi:10.1097/00008877-199302000-00001 · Cited by 129
Self-injection of d,1-3,4-methylenedioxymethamphetamine (MDMA) in the baboon
Lamb, R. J., & Griffiths, R. R. (1987) · Psychopharmacology · doi:10.1007/bf00518175 · Cited by 127
Ricaurte, G. A., McCann, U., Szabò, Z., & Scheffel, U. (2000) · Toxicology Letters · doi:10.1016/s0378-4274(99)00216-7 · Cited by 122
Chait, L. D., UHLENHUTH, E. H., & Johanson, C. E. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90503-4 · Cited by 102
Self-citationElectrophysiological Evidence of Serotonergic Impairment in Long-Term MDMA (“Ecstasy”) Users
Croft, R. J., Klugman, A., Baldeweg, T., & Gruzelier, J. H. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1687 · Cited by 101
Reinforcing and subjective effects of several anorectics in normal human volunteers.
Chait, L. D., UHLENHUTH, E. H., & Johanson, C. E. (1987) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)39173-1 · Cited by 101
Self-citationJones, H. E., Garrett, B. E., & Griffiths, R. R. (1999) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37941-8 · Cited by 98
Dafters, R. I., Duffy, F., O'Donnell, P. J., & Bouquet, C. (1999) · Psychopharmacology · doi:10.1007/s002130051035 · Cited by 95
An Exploration of the History and Controversies Surrounding MDMA and MDA
Pentney, A. R. (2001) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2001.10400568 · Cited by 94
Benkelfat, C. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810280099018 · Cited by 93
McCann, U., Mertl, M., Murphy, D. L., Eligulashvili, V., & Ricaurte, G. A. (1999) · Psychopharmacology · doi:10.1007/s002130051142 · Cited by 85
Hansen, J., Riddle, E. L., Sandoval, V., Brown, J. M., Gibb, J. W., Hanson, G. R., & Fleckenstein, A. E. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.3.1093 · Cited by 76
Fischman, M. W. (1989) · PubMed · Cited by 69
Chait, L. D., UHLENHUTH, E. H., & Johanson, C. E. (1986) · Psychopharmacology · doi:10.1007/bf00174364 · Cited by 64
Self-citationAbecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects.
Mumford, G. K., Rush, C. R., & Griffiths, R. R. (1995) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)24438-x · Cited by 59
Buydens‐Branchey, L., Branchey, M. H., Fergeson, P., Hudson, J., & McKernin, C. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00182-5 · Cited by 57
Evaluation of Phentermine and Fenfluramine, Alone and in Combination, in Normal, Healthy Volunteers
Brauer, L. H. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00113-r · Cited by 53
Abuse liability assessment of sibutramine, a novel weight control agent
Schuh, L. M., Schuster, C. R., Hopper, J. A., & Mendel, C. M. (2000) · Psychopharmacology · doi:10.1007/s002130050001 · Cited by 52
Executive function in abstinent MDMA ('ecstasy') users.
Kk, Z., & Da, Y. (2002) · PubMed · Cited by 45
Specific neurotoxicity of chronic use of ecstasy
Obrocki, J., Schmoldt, A., Buchert, R., Andresen, B., Petersen, K. U., & Thomasius, R. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00511-2 · Cited by 43
‘Is MDMA a Human Neurotoxin?’:Diverse Views from the Discussants
Turner, J. J., & Parrott, A. C. (2000) · Neuropsychobiology · doi:10.1159/000026669 · Cited by 27
Fischman, M. W. (1989) · PsycEXTRA Dataset · doi:10.1037/e468292004-001 · Cited by 26
A Drug Preference Procedure for use with Human Volunteers
de Wit, H., & Johanson, C. E. (1987) · Springer eBooks · doi:10.1007/978-1-4612-4812-5_26 · Cited by 21
Self-citationEcstasy: Dangers and Controversies
Pham, J. V., & Puzantian, T. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.20.1561.34474 · Cited by 17
Cited by
Sorted by citations
Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., Martin, S. F., Yazar‐Klosinski, B., Michel, Y., Brewerton, T. D., & Doblin, R. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112456611 · Cited by 399
Clinical toxicology of newer recreational drugs
Hill, S. L., & Thomas, S. H. L. (2011) · Clinical Toxicology · doi:10.3109/15563650.2011.615318 · Cited by 288
Molecular and Cellular Mechanisms of Ecstasy-Induced Neurotoxicity: An Overview
Capela, J. P., Carmo, H., Remião, F., Bastos, M. D. L., Meisel, A., & Carvalho, F. D. (2009) · Molecular Neurobiology · doi:10.1007/s12035-009-8064-1 · Cited by 294
Baumann, M. H., Wang, X., & Rothman, R. B. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0322-6 · Cited by 258
Bedi, G., Hyman, D., & de Wit, H. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.08.003 · Cited by 247
Metadata
- Authors
- Tancer, M., & Johanson, C.-E.
- Affiliations
- Wayne State University (US)
- Corresponding author
- Tancer, Manuel
- Venue
- Drug and Alcohol Dependence
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 72
- Issue
- 1
- Pages
- 33-44
- ISSN
- 0376-8716 (ISSN-L)
- OpenAlex
- W2127854642
- Cited by
- 153
- References
- 58
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 8 · 2020: 3 · 2019: 6 · 2018: 12 · 2017: 8 · 2016: 7 · 2015: 5 · 2014: 13 · 2013: 7 · 2012: 10
- FWCI
- 8.16
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Drug and Alcohol Dependence (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08da000370-05)
- National Institute on Drug Abuse (5 K08 DA00370)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- MDMA, 3,4-methylenedioxymethamphetamine, d-amphetamine, mCPP, serotonin release, dopamine release, drug reinforcement, subjective effects, physiological effects, dose dependence
- MeSH terms
- Adolescent, Adult, Affect, Dextroamphetamine, Female, Hallucinogens, Humans, Hydrocortisone, Male, Piperazines, Surveys and Questionnaires, Reinforcement, Psychology, Severity of Illness Index, Serotonin Receptor Agonists, Dopamine Agonists, Cross-Over Studies, N-Methyl-3,4-methylenedioxyamphetamine, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
